再発/難治性多発性骨髄腫の参加者におけるベランタマブ マフォドチン、ボルテゾミブ、デキサメタゾンとダラツムマブ、ボルテゾミブ、デキサメタゾンの有効性と安全性の評価 (DREAMM 7)
DREAMM 7:ベランタマブ マフォドチン、ボルテゾミブ、およびデキサメタゾンの組み合わせ (B-Vd) の有効性と安全性を、ダラツムマブ、ボルテゾミブ、およびデキサメタゾンの組み合わせ (D-Vd) と比較して評価するための多施設非盲検無作為化第 III 相試験) 再発/難治性多発性骨髄腫の参加者
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究場所
-
-
Arizona
-
Yuma、Arizona、アメリカ、85364
- GSK Investigational Site
-
-
Kansas
-
Mission、Kansas、アメリカ、66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver、North Carolina、アメリカ、80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash、Ohio、アメリカ、45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler、Texas、アメリカ、75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke、Virginia、アメリカ、24014
- GSK Investigational Site
-
-
-
-
-
Bournemouth、イギリス、BH7 7DW
- GSK Investigational Site
-
Cardiff、イギリス、CF14 4XW
- GSK Investigational Site
-
Dundee、イギリス、DD1 9SY
- GSK Investigational Site
-
Leicester、イギリス、LE1 5WW
- GSK Investigational Site
-
London、イギリス、W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent、イギリス、ST4 6QG
- GSK Investigational Site
-
Sutton、イギリス、SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Jerusalem、イスラエル、91120
- GSK Investigational Site
-
Kfar Saba、イスラエル、44281
- GSK Investigational Site
-
Ramat Gan、イスラエル、52621
- GSK Investigational Site
-
Tel Aviv、イスラエル、64239
- GSK Investigational Site
-
-
-
-
-
Bergamo、イタリア、24127
- GSK Investigational Site
-
Bologna、イタリア、40138
- GSK Investigational Site
-
Brescia、イタリア、25123
- GSK Investigational Site
-
Catania、イタリア、95123
- GSK Investigational Site
-
Meldola FC、イタリア、47014
- GSK Investigational Site
-
Milan、イタリア、20133
- GSK Investigational Site
-
Ravenna、イタリア、48121
- GSK Investigational Site
-
Roma、イタリア、00168
- GSK Investigational Site
-
Siena、イタリア、53100
- GSK Investigational Site
-
Torino、イタリア、10126
- GSK Investigational Site
-
-
-
-
-
Groningen、オランダ、9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht、South Holland、オランダ、3318 AT
- GSK Investigational Site
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- GSK Investigational Site
-
Liverpool、New South Wales、オーストラリア、2170
- GSK Investigational Site
-
Newcastle、New South Wales、オーストラリア、2298
- GSK Investigational Site
-
St Leonards、New South Wales、オーストラリア、2065
- GSK Investigational Site
-
Wollongong、New South Wales、オーストラリア、2500
- GSK Investigational Site
-
-
Queensland
-
Benowa、Queensland、オーストラリア、4217
- GSK Investigational Site
-
Herston、Queensland、オーストラリア、4029
- GSK Investigational Site
-
-
South Australia
-
Ashford、South Australia、オーストラリア、5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- GSK Investigational Site
-
Heidelberg、Victoria、オーストラリア、3084
- GSK Investigational Site
-
Melbourne、Victoria、オーストラリア、3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch、Western Australia、オーストラリア、6150
- GSK Investigational Site
-
Nedlands、Western Australia、オーストラリア、6009
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- GSK Investigational Site
-
Toronto、Ontario、カナダ、M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal、Quebec、カナダ、H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Athens、ギリシャ、11528
- GSK Investigational Site
-
Thessaloniki、ギリシャ、54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli、East Macedonia and Thrace、ギリシャ、681 00
- GSK Investigational Site
-
-
-
-
-
Barcelona、スペイン、08035
- GSK Investigational Site
-
Barcelona、スペイン、08916
- GSK Investigational Site
-
Cáceres、スペイン、10003
- GSK Investigational Site
-
Gijón、スペイン、33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega、スペイン、08908
- GSK Investigational Site
-
MOstoles Madrid、スペイン、28933
- GSK Investigational Site
-
Madrid、スペイン、28007
- GSK Investigational Site
-
Madrid、スペイン、31008
- GSK Investigational Site
-
Murcia、スペイン、30008
- GSK Investigational Site
-
PamplonaNavarra、スペイン、31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr、スペイン、28223
- GSK Investigational Site
-
Salamanca、スペイン、37007
- GSK Investigational Site
-
-
-
-
-
Brno、チェコ、625 00
- GSK Investigational Site
-
Hradec Králové、チェコ、500 05
- GSK Investigational Site
-
Ostrava、チェコ、708 52
- GSK Investigational Site
-
Prague、チェコ、128 08
- GSK Investigational Site
-
-
-
-
-
Cologne、ドイツ、50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm、Baden-Wurttemberg、ドイツ、89081
- GSK Investigational Site
-
-
Bavaria
-
München、Bavaria、ドイツ、81377
- GSK Investigational Site
-
Würzburg、Bavaria、ドイツ、97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf、North Rhine-Westphalia、ドイツ、40225
- GSK Investigational Site
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07747
- GSK Investigational Site
-
-
-
-
-
Christchurch、ニュージーランド、8011
- GSK Investigational Site
-
Dunedin、ニュージーランド、9054
- GSK Investigational Site
-
Takapuna Auckland、ニュージーランド、1309
- GSK Investigational Site
-
Wellington、ニュージーランド、6021
- GSK Investigational Site
-
-
-
-
-
Amiens、フランス、80054
- GSK Investigational Site
-
Caen、フランス、14033
- GSK Investigational Site
-
Nice、フランス、06200
- GSK Investigational Site
-
Paris、フランス、75651
- GSK Investigational Site
-
Rennes、フランス、35033
- GSK Investigational Site
-
-
-
-
-
Joinville、ブラジル、89201-260
- GSK Investigational Site
-
Natal、ブラジル、59075-740
- GSK Investigational Site
-
Rio de Janeiro、ブラジル、22775001
- GSK Investigational Site
-
São Paulo、ブラジル、04537-080
- GSK Investigational Site
-
São Paulo、ブラジル、05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、ブラジル、88020-210
- GSK Investigational Site
-
-
-
-
-
Roeselare、ベルギー、8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette、Brussels Capital、ベルギー、1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert、Brussels Capital、ベルギー、1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- GSK Investigational Site
-
-
-
-
-
Chorzów、ポーランド、41-500
- GSK Investigational Site
-
Krakow、ポーランド、30510
- GSK Investigational Site
-
Lodz、ポーランド、93-513
- GSK Investigational Site
-
Lublin、ポーランド、20-081
- GSK Investigational Site
-
Lublin、ポーランド、20-090
- GSK Investigational Site
-
Nowy Sącz、ポーランド、33-300
- GSK Investigational Site
-
Poznan、ポーランド、60-569
- GSK Investigational Site
-
Warsaw、ポーランド、02-781
- GSK Investigational Site
-
-
-
-
-
Moscow、ロシア、125284
- GSK Investigational Site
-
Nizhny Novgorod、ロシア、603126
- GSK Investigational Site
-
Novosibirsk、ロシア、630087
- GSK Investigational Site
-
Saint Petersburg、ロシア、191024
- GSK Investigational Site
-
Saint Petersburg、ロシア、197 089
- GSK Investigational Site
-
Samara、ロシア、443021
- GSK Investigational Site
-
Saratov、ロシア、410028
- GSK Investigational Site
-
Ufa、ロシア、450083
- GSK Investigational Site
-
-
-
-
-
Beijing、中国、100191
- GSK Investigational Site
-
Beijing、中国、100020
- GSK Investigational Site
-
Changchun、中国、130012
- GSK Investigational Site
-
Guangzhou、中国、510060
- GSK Investigational Site
-
Guangzhou、中国、510515
- GSK Investigational Site
-
Hangzhou、中国、310003
- GSK Investigational Site
-
Jinan、中国、250012
- GSK Investigational Site
-
Nanjing、中国、210008
- GSK Investigational Site
-
Shenyang、中国、110001
- GSK Investigational Site
-
Suzhou、中国、215006
- GSK Investigational Site
-
Tianjin、中国、300020
- GSK Investigational Site
-
Zhengzhou、中国、450052
- GSK Investigational Site
-
-
-
-
-
Aichi、日本、467-8602
- GSK Investigational Site
-
Aichi、日本、441-8570
- GSK Investigational Site
-
Aomori、日本、030-8553
- GSK Investigational Site
-
Ehime、日本、790-8524
- GSK Investigational Site
-
Fukuoka、日本、806-8501
- GSK Investigational Site
-
Fukuoka、日本、807-8555
- GSK Investigational Site
-
Fukuoka、日本、810-8563
- GSK Investigational Site
-
Fukuoka、日本、815-8555
- GSK Investigational Site
-
Gifu、日本、503-8502
- GSK Investigational Site
-
Gunma、日本、377-0280
- GSK Investigational Site
-
Hyōgo、日本、670-8540
- GSK Investigational Site
-
Kanagawa、日本、247-8533
- GSK Investigational Site
-
Kanagawa、日本、221-0855
- GSK Investigational Site
-
Kochi、日本、781-8555
- GSK Investigational Site
-
Nagano、日本、392-8510
- GSK Investigational Site
-
Okayama、日本、701-1192
- GSK Investigational Site
-
Osaka、日本、545-8586
- GSK Investigational Site
-
Osaka、日本、530-0012
- GSK Investigational Site
-
Shizuoka、日本、411-8777
- GSK Investigational Site
-
-
-
-
-
Pusan、韓国、49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do、韓国、13620
- GSK Investigational Site
-
Seoul、韓国、06351
- GSK Investigational Site
-
Seoul、韓国、06591
- GSK Investigational Site
-
Ulsan、韓国、44033
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ベランタマブ マホドチンおよびボルテゾミブとデキサメタゾン (アーム A)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
アクティブコンパレータ:ダラツムマブおよびボルテゾミブとデキサメタゾン (アーム B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS)
時間枠:Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
眼科検査で眼に異常所見を認めた参加者数
時間枠:最長73ヶ月
|
最長73ヶ月
|
|
|
Complete Response Rate (CRR)
時間枠:Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
時間枠:Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
時間枠:Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
時間枠:Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
時間枠:Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
時間枠:Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
時間枠:Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
時間枠:Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
時間枠:Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
時間枠:Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
時間枠:Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
時間枠:Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
時間枠:Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
時間枠:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
時間枠:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
時間枠:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
時間枠:Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
時間枠:Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
時間枠:Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
時間枠:Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
時間枠:Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:GSK Clinical Trials、GlaxoSmithKline
出版物と役立つリンク
一般刊行物
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 207503
- 2018 (米国 NIH グラント/契約)
- 2018-003993-29 (レジストリ識別子:EudraCT (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。